UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2018
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact name of registrant as specified in its
charter)
Delaware | 001-34236 | 11-3054851 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
35 Wilbur Street | 11563 |
Lynbrook, NY | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: 516.593.7000
N/A
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Introductory Comment
Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.
Item 8.01. | Other Events |
On March 12, 2018, the Company announced the presentation of interim data from its ongoing Phase 1 Study of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids at the 65th Annual Scientific Meeting of the Society for Reproductive Investigation on Friday, March 9, 2018, in San Diego, CA.
A press release regarding the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. | Financial Statements and Exhibits |
(d) |
Exhibits. |
Exhibit | Description |
99.1 | Press Release dated March 12, 2018 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 12, 2018
BioSpecifics Technologies Corp. | |
By: | /s/ Thomas L. Wegman |
Name: Thomas L. Wegman | |
Title: President |
3
BioSpecifics Technologies Corp. Announces Presentation of
Interim Data from Phase 1 Study of CCH for the Treatment of
Uterine Fibroids at 65th Annual Scientific Meeting of the Society
for Reproductive Investigation
LYNBROOK, NY March 12, 2018 BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the presentation of interim data from its ongoing Phase 1 trial of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids at the 65th Annual Scientific Meeting of the Society for Reproductive Investigation on Friday, March 9, 2018 in San Diego, CA. The data show the safety and effectiveness of the CCH injection method in five patients.
These interim data are very encouraging and show not only a significant reduction of collagen content but also the disruption of the tissue pattern in the uterine fibroids injected with CCH, said Thomas L. Wegman, President of BioSpecifics. Although uterine fibroids are the most prevalent tumor of the female reproductive tract, non-surgical treatments are extremely limited and this is the first trial assessing the treatment of uterine fibroids using injectable collagenase. We believe there are strong benefits to a treatment that can effectively reduce the size and stiffness of the fibroids which will ultimately decrease symptoms of pain and bleeding, avoid the need for surgical procedures and result in a better quality of life for these affected women.
Three patients were injected with CCH and underwent a hysterectomy 24-96 hours after the injection. Two patients subsequently were injected with a higher dose of collagenase, and underwent a hysterectomy 63 days after the injection. The collagenase-treated tissue samples showed not only a significant reduction of collagen content but also the disruption of the tissue pattern, while in control tissues the collagen remained abundant and compact. The digestion of collagen did not extend beyond the capsule of any fibroid. No adverse event occurred in these patients.
The Phase 1 open-label dose escalation study is being conducted at the Department of Gynecology & Obstetrics at Johns Hopkins University and will enroll a total of 15 female subjects treated prior to hysterectomy. The primary endpoint will assess the safety and tolerability of a single injection of XIAFLEX directly into the uterine fibroids at three doses under transvaginal ultrasound guidance. The secondary endpoints will assess symptoms of pain and bleeding, quality of life throughout the study, shrinkage of XIAFLEX treated fibroids in size, increased rates of apoptosis in treated fibroids and a decrease in the collagen content of treated fibroids.
1
About Uterine Fibroids
Uterine fibroids are very common benign tumors in the reproductive tract that contain large amounts of collagen which may cause pelvic discomfort and pain, decreased fertility, pregnancy complications, an increased rate of miscarriage, uterine bleeding, prolonged menstrual bleeding and frequent urination. Uterine fibroids are the leading cause of hysterectomies in the U.S., accounting for about 250,000 hysterectomies and 30,000 myomectomies performed each year. Uterine fibroids have been estimated to cost up to $9.4 billion annually in direct costs in the U.S. and there is a high level of recurrence with current treatment options.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. The CCH research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of CCH for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit www.biospecifics.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, expected revenue growth, and the assumptions underlying or relating to such statements, are "forward-looking statements." The forward-looking statements in this press release include statements concerning, among other things, the progression of our Phase 1 clinical trial of CCH for the treatment of uterine fibroids; whether and when we will report data from our Phase 1 clinical trial of CCH for the treatment of uterine fibroids and whether CCH treatment will result in strong benefits that can reduce the size and stiffness of uterine fibroids, decrease associated symptoms, avoid the need for surgical procedures and result in better quality of life for affected women. In some cases, these statements can be identified by forward-looking words such as "believe," "expect," "plan", "may," "will," "can," and "could," the negative or plural of these words, and other similar expressions. These forward-looking statements are predictions based on BioSpecifics' current expectations and its projections about future events and various assumptions. There can be no assurance that BioSpecifics will realize its expectations or that BioSpecifics' beliefs will prove correct. There are a number of important factors that could cause BioSpecifics' actual results to differ materially from those indicated by such forward-looking statements, including the timing of regulatory filings and action; the ability of Endo and its partners, Asahi Kasei Pharma Corporation, Actelion Ltd. and Swedish Orphan Biovitrum AB, to achieve their objectives for XIAFLEX in their applicable territories; the market for XIAFLEX in, and timing, initiation and outcome of clinical trials for additional indications that will determine the amount of milestone, royalty, mark-up on cost of goods sold, license and sublicense income BioSpecifics may receive; the potential of XIAFLEX to be used in additional indications; Endo modifying its objectives or allocating resources other than to XIAFLEX; and other risk factors identified in BioSpecifics' Annual Report on Form 10-K for the year ended December 31, 2016, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2017, June 30, 2017 and September 30, 2017 and its Current Reports on Form 8-K filed with the Securities and Exchange Commission. All forward-looking statements included in this press release are made as of the date hereof, are expressly qualified in their entirety by the cautionary statements included in this press release and, except as may be required by law, BioSpecifics assumes no obligation to update these forward-looking statements.
2
Contact:
BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com
3
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end